TUBA3C
ENSG00000198033
Target class
Structural protein
Chromosome
13
Approved drugs
19
Clinical candidates (approved and in development)
83
- Approved drugs
- 19
- Clinical candidates (approved and in development)
- 83
- Chemical probe available
- No
- Other names
- bA408E5.3
- Target name
- TUBA3C
- Gene name
- Tubulin alpha 3c
- Gene symbol
- TUBA3C
- Previous gene symbols
- TUBA2
- Protein name
- Tubulin alpha-3C chain (EC 3.6.5.-) (Alpha-tubulin 2) (Alpha-tubulin 3C) (Tubulin alpha-2 chain) [Cleaved into: Detyrosinated tubulin alpha-3C chain]
- Gene biotype
- Protein coding
- Gene family
- Tubulin alpha family
- Target class
- Structural protein
- Target type
- Human gene
- Tissues expressed in
- 1
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 956.49
- Tissue specificity (Gini)
- 0.981
- Tissue specificity (tau)
- 1
- Protein interaction confidence
- 0.7223
- Protein interaction partners
- 10
- hsa:113457
- hsa:7278
- R-HSA-1445148
- R-HSA-190840
- R-HSA-190861
- R-HSA-2132295
- R-HSA-2467813
- R-HSA-2500257
- R-HSA-3371497
- R-HSA-380320
- R-HSA-389957
- R-HSA-389960
- R-HSA-389977
- R-HSA-437239
- R-HSA-5610787
- R-HSA-5620920
- R-HSA-5620924
- R-HSA-5626467
- R-HSA-5663220
- R-HSA-6807878
- R-HSA-6811434
- R-HSA-6811436
- R-HSA-68877
- R-HSA-8852276
- R-HSA-8955332
- R-HSA-9609690
- R-HSA-9609736
And 6 more, listed on the interactive page.
- End position
- 19181824
- Start position
- 19173772
- Chromosome
- 13
- Strand
- Reverse
- Cytoplasm, cytoskeleton.
- Microtubules
- Primary cilium
- Tissue specificity (tau)
- 0.999969
- Expression inequality (Gini)
- 0.980913
Expression in transcripts per million
- Testis
- 956.49
- Stomach
- 0.36
- Cervix - Ectocervix
- 0.12
- Heart - Left Ventricle
- 0.07
- Spleen
- 0.07
Expression in transcripts per million
- Testis956.49
- Stomach0.36
- Cervix - Ectocervix0.12
- Heart - Left Ventricle0.07
- Spleen0.07
- Fallopian Tube0.07
- Uterus0.07
- Ovary0.06
- Prostate0.06
- Brain - Cerebellum0.05
- Esophagus - Mucosa0.05
- Pituitary0.05
- Minor Salivary Gland0.05
- Small Intestine - Terminal Ileum0.05
- Adrenal Gland0.04
- Skin - Not Sun Exposed (Suprapubic)0.04
- Liver0.04
- Cervix - Endocervix0.04
- Heart - Atrial Appendage0.04
- Pancreas0.03
- Brain - Hypothalamus0.03
- Thyroid0.03
- Cells - Cultured fibroblasts0.03
- Esophagus - Muscularis0.03
- Colon - Transverse0.03
And 29 more, listed on the interactive page.
- GO:0005634
- GO:0005929
- GO:0015630
Related records
Trials (9,112)
- 'ADVANCE' (A Pilot Trial)
- "Curcumin" in Combination With Chemotherapy in Advanced Breast Cancer
- "Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"
- "Prevention of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients"
- [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
- [18F]Fluciclatide-PET, Pazopanib and Paclitaxel in Ovarian Cancer
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
- 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
- 1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
- 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
- 12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
- 1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- 17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor
- 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
- 2-arm Trial of Paclitaxel Plus Bevacizumab vs. Capecitabine Plus Bevacizumab
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- 3-AP Plus Cisplatin and Paclitaxel in Treating Patients With Advanced or Metastatic Cancer
Drugs (88)
- AGS-16C3F Tubulin disrupting agent
- Anetumab ravtansine Tubulin inhibitor
- ANG1005 Tubulin inhibitor
- Anvatabart opadotin Tubulin inhibitor
- Aprutumab ixadotin Tubulin inhibitor
- ASG-5ME Tubulin inhibitor
- AVE-9633 Tubulin inhibitor
- Azintuxizumab vedotin Tubulin inhibitor
- Belantamab mafodotin Tubulin inhibitor
- BIIB-015 Tubulin inhibitor
- Bivatuzumab mertansine Tubulin inhibitor
- BMS-275183 Tubulin stabiliser
- Brentuximab vedotin Tubulin inhibitor
- Cabazitaxel Tubulin inhibitor
- Cantuzumab mertansine Tubulin inhibitor
- Cantuzumab ravtansine Tubulin inhibitor
- Colchicine Tubulin inhibitor
- Coltuximab ravtansine Tubulin inhibitor
- Crolibulin Tubulin inhibitor
- Davunetide Tubulin stabiliser